Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.39 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27095265 | 0.80 | IDH1 (0.39) | CYP11B1CYP11B2IDH1 | |
| SCHEMBL27095194 | 0.80 | IDH1 (0.39) | CYP11B1CYP11B2IDH1 | |
| Hydrochloric Acid SCHEMBL30838036 | 0.77 | IDO1 (0.43) | MAPK1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838016 | 0.76 | IDH2 (0.50) | — | |
| Hydrochloric Acid SCHEMBL30838002 | 0.76 | IDH2 (0.50) | — | |
| SCHEMBL24288094 | 0.74 | CYP11B2 (0.41) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838043 | 0.74 | CHEK1 (0.42) | — | |
| Hydrochloric Acid SCHEMBL30838067 | 0.74 | CHEK1 (0.42) | — | |
| SCHEMBL27095185 | 0.74 | CYP11B1 (0.39) | CYP11B1CYP11B2IDH1 | |
| SCHEMBL27148103 | 0.74 | CYP11B1 (0.39) | CYP11B1CYP11B2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | MAPK1 3497/4885CYP11B1 1707/4885CYP11B2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.